Haihua Yuan

Shenzhen Haihua Yuan Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative long-acting peptide therapeutics for metabolic and chronic diseases. Headquartered in Shenzhen, China, the company utilizes proprietary protein engineering and modification platforms to extend the half-life and enhance the efficacy of peptide-based drugs. Its lead candidate, HH-018, is a long-acting GLP-1 receptor agonist currently undergoing clinical trials for the treatment of type 2 diabetes and obesity. The company's pipeline also includes multi-target agonists, such as GLP-1/GIP dual agonists and GLP-1/GIP/Glucagon triple agonists, aimed at addressing complex metabolic disorders like NASH. Haihua Yuan is backed by prominent Chinese venture capital firms and strives to provide patients with more effective and convenient treatment options.